retatrutide

Lilly’s triple-agonist drug cuts weight 21% in diabetes trial

Eli Lilly announced on Tuesday that its experimental drug retatrutide helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial, marking the largest weight reduction ever recorded…

Lilly plans Q1 2027 FDA filing for obesity drug retatrutide

Eli Lilly announced Thursday that it will submit a Biologics License Application for its next-generation obesity drug retatrutide to the U.S. Food and Drug Administration in the first quarter of 2027, after reporting positive results from two additional Phase 3…